168 related articles for article (PubMed ID: 25892147)
1. Ibrutinib in pretreated Waldenström's macroglobulinaemia.
Bagcchi S
Lancet Oncol; 2015 May; 16(5):e204. PubMed ID: 25892147
[No Abstract] [Full Text] [Related]
2. ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
Prescrire Int; 2016 Oct; 25(175):232. PubMed ID: 30645823
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
4. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Grunenberg A; Buske C
Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
[TBL] [Abstract][Full Text] [Related]
5. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia.
Treon SP; Xu L; Hunter Z
N Engl J Med; 2015 Aug; 373(6):584-6. PubMed ID: 26244327
[No Abstract] [Full Text] [Related]
6.
Gustine JN; Xu L; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Keezer A; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ
Blood Adv; 2019 Oct; 3(19):2800-2803. PubMed ID: 31570491
[No Abstract] [Full Text] [Related]
7. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Carroll C; Stevens J; Simpson E; Thokala P; Wong R; Wright J; Auer R
Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
[TBL] [Abstract][Full Text] [Related]
8. Preclinical models of Waldenström's macroglobulinemia and drug resistance.
Ailawadhi S; Paulus A; Chanan-Khan A
Best Pract Res Clin Haematol; 2016 Jun; 29(2):169-178. PubMed ID: 27825463
[TBL] [Abstract][Full Text] [Related]
9. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.
Cheng MP; Kusztos AE; Gustine JN; Dryden-Peterson SL; Dubeau TE; Woolley AE; Hammond SP; Baden LR; Treon SP; Castillo JJ; Issa NC
Br J Haematol; 2019 May; 185(4):788-790. PubMed ID: 30460682
[No Abstract] [Full Text] [Related]
10. Updates in prognostication and treatment of Waldenström's macroglobulinemia.
Advani P; Paulus A; Ailawadhi S
Hematol Oncol Stem Cell Ther; 2019 Dec; 12(4):179-188. PubMed ID: 31158330
[TBL] [Abstract][Full Text] [Related]
11. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
12. Standard Dose of Ibrutinib is Effective in the Treatment of Bing-Neel Syndrome.
Plander M; Szendrei T; Vadvári Á; Iványi J
Pathol Oncol Res; 2020 Jan; 26(1):591-592. PubMed ID: 30357751
[No Abstract] [Full Text] [Related]
13. Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement.
Hiemcke-Jiwa LS; Leguit RJ; Radersma-van Loon JH; Westerweel PE; Rood JJM; Doorduijn JK; Huibers MMH; Minnema MC
Leuk Lymphoma; 2018 May; 59(5):1256-1259. PubMed ID: 28849690
[No Abstract] [Full Text] [Related]
14. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.
Lim KJC; Tam CS
Expert Opin Pharmacother; 2020 Sep; 21(13):1555-1564. PubMed ID: 32603202
[TBL] [Abstract][Full Text] [Related]
15. First-line ibrutinib for Bing-Neel syndrome.
Tallant A; Selig D; Wanko SO; Roswarski J
BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30279255
[TBL] [Abstract][Full Text] [Related]
16. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
[TBL] [Abstract][Full Text] [Related]
17. Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.
Tripathi A; Steingart R
J Oncol Pract; 2016 May; 12(5):490-1. PubMed ID: 27170696
[No Abstract] [Full Text] [Related]
18. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Parrondo RD; Dutta N; LaPlant BR; Elliott J; Fernandez A; Zimmerman A; Cicco G; Han B; Heslop K; Chapin D; Sher T; Roy V; Rasheed A; Das S; Chanan-Khan AA; Paulus A; Ailawadhi S
Br J Haematol; 2024 May; 204(5):1825-1829. PubMed ID: 38286472
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib in the management of Waldenstrom macroglobulinemia.
Yosef A; Touloukian EZ; Nambudiri VE
J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737
[TBL] [Abstract][Full Text] [Related]
20. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.
Vos JM; Tsakmaklis N; Patterson CJ; Meid K; Castillo JJ; Brodsky P; Ganz T; Pals ST; Kersten MJ; Xu L; Yang G; Treon SP; Hunter ZR
Haematologica; 2017 Nov; 102(11):e452-e455. PubMed ID: 28798070
[No Abstract] [Full Text] [Related]
[Next] [New Search]